aqc 2016 patient centered survey final...
TRANSCRIPT
![Page 1: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/1.jpg)
AQC2016SurveyResearch
FinalReportofPatientSurveyandAQCMemberSurveyData
October2016
![Page 2: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/2.jpg)
2
UsageGuidelines
Proprietary&Confidential– NoreproductionoftheinformationinthisreportmaybemadewithouttheexpresspriorwrittenconsentofTheAvocaGroup.Allinquiriesandrequestsforconsentforreproductionanduse,includingintegratingelementsofthisreportintotherecipients’ownworkproducts(e.g.,presentations),shouldbedirectedtoLakshmiSundarviaemailatLakshmi.Sundar@theavocagroup.com.
![Page 3: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/3.jpg)
3
Introduction:2016AQCSurveyPrograms
Introduction
• The2016AQCSurveyResearchProgramhadtwocomponents– AQC’sfirstPatientSurvey,andanabbreviatedversionoftheannualMemberSurvey.InclusionofthePatientSurveyin2016wasrelatedtoAQC’sobjectivetounderstandclinicalresearchquality,andhowitmightbeimproved,fromtheviewpointofallkeystakeholders.
• TheoverallobjectivesoftheAQCPatientSurveyweretogainanunderstandingof:
– theextenttowhichpatientsperceivethattheirmedicalcareprovidersunderstandvariousaspectsofthepatientexperience,
– patientperceptionsof“quality”andvalueinclinicalresearch,aswellasactionsbyresearchersthatmightpositivelyandnegativelyimpacttheseperceptions,and
– factorsthatdrivepatients’desirestoparticipateandcontinueinclinicaltrials.
• Theobjectiveofthe2016AQCMemberSurveywastoexaminequalitytopicsinamannerthatparalleledthePatientSurvey,aswellastocontinuetofollowMemberperceptionsofkeyqualityindicatorsovertime.
![Page 4: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/4.jpg)
4
Methodology:PatientSurvey
Introduction
• ThePatientSurveywasaweb-basedsurveyofadults(≥18yearsold),UnitedStatesresidentswhoself-identifiedas“patients”withanymedicalconditionandwhocouldread,understand,andcompleteaweb-basedsurveyintheEnglishlanguage.Thestudyrecruited582peoplefittingthisdescription.
• PotentialparticipantswerecontactedbyemailusingemailaddressesfromthePMGResearch,PLM(PatientsLikeMe),andCISCRP(CenterforInformationandStudyonClinicalResearchParticipation)databases,aswellastheAQCMembership.Allcontactsweremadebytheoriginatingorganizations;therewasnotransferofemailaddressesoranyotherpotentiallyidentifyingpatientinformationtootherorganizations(includingTheAvocaGroup),aspartofthisresearch,norwasanypotentiallyidentifyinginformationgatheredduringthesurveyprocess.
• Thisminimal-riskresearchprojectwasreviewedbyWIRBandgrantedexemptstatus.
![Page 5: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/5.jpg)
5
Methodology:AQCMemberSurvey
Introduction
• TheAQCMembersurveywasaweb-basedsurveyofSponsorandCROAvocaQualityConsortiumMembers.
• Atotalof188respondentscompletedthesurvey,amongkeyaudiencesasfollows:
– 103fromSponsororganizations
– 85fromCROs
• AllsurveyswerecompletedbetweenMarchandJuneof2016.
![Page 6: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/6.jpg)
6
CharacteristicsofthePatientSample
![Page 7: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/7.jpg)
7
54%
21%
19%6% Married/domesticpartner
Divorced/separated
Single
Widow/widower
Thesamplewaspredominantlyfemale,and82%ofparticipantswereoverage45.Approximatelyhalfofrespondentswerelivinginmarriages/domesticpartnerships,andthevastmajority(84%)residedintheEasternorMidwesternUS.
CharacteristicsofPatientSample:Demographics
13%3%
13%
21%
50%
West,Southwest
Mountain
Midwest
Northeast
Southeast
MaritalStatus
N=491
N=494
73%
27%Female
Male
Sex
3%15%
38%
39%
5% 18to30
31to45
46to60
61to75
76+
N=492
AgeRegionwithintheUS
N=497
![Page 8: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/8.jpg)
8
CharacteristicsofPatientSample:MedicalConditions
9%
29%59%
Temporary(expectittogoawaycompletelyatsomepoint)Episodic(comesandgoes)Degenerative(getsworseovertime)Chronic(alwaysthere)butstableDon’tknow
7%12%
17%
34%
29%
None
Itvariesalotovertime
Mild
Moderate
Severe
Don’tknow
Howoftendoyouseethedoctorresponsiblefortreatingyourcondition?
12%
48%20%
9%10% Onceperyearorless
2to4timesperyear
5to12timesperyear
Morethan12timesperyear
Itdepends
Can'trecall
Themajorityofrespondentsreportedchronicordegenerativemedicalconditions,andmostexperiencedmoderateorsevereimpactsontheirlives.Abouttwo-thirdssawtheirtreatingdoctorsbetween2and12timesperyear.
ImpactofMedicalCondition
N=580
TypeofMedicalCondition
N=581
N=582
![Page 9: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/9.jpg)
9
42%
58%
Yes
No
24%
13%
31%
32%Fulltime
Parttime
Retired
No
23%
33%
32%
11% Advanceddegree
Completedcollegedegree
Somecollege
Completedhighschool
Somehighschool
Respondentswerelargelywell-educated,withmorethanhalfpossessingacollegedegree.Approximatelyathirdwereemployed,one-quarterfull-time.Slightlyunderhalfwererelieduponbyfamilymembersfordirectcareorfinancialsupport.
CharacteristicsofPatientSample:EducationandEmployment
Doyouhavefamilymembersforwhomyouprovidecareorfinancialsupport?
HighestLevelofEducation
N=497
N=578
Areyoucurrentlyemployed?
N=581
![Page 10: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/10.jpg)
10
CharacteristicsoftheAQCMemberSample
![Page 11: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/11.jpg)
11
CharacteristicsofAQCMemberSample:Companies
Sponsors103respondentsfrom27Membercompanies
#ofrespondentspercompanyrangedfrom1to11
CROs85respondentsfrom6Membercompanies
#ofrespondentspercompanyrangedfrom5to32
Alexion Horizon
Alnylam Infinity
Amgen MitsubishiTanabePharma
Astellas Novartis
Biogen Pfizer
BoehringerIngelheim Pharmacyclics
BristolMyersSquibb Purdue
CSLBehring Raptor
Cidara Roche
EliLilly SeattleGenetics
Endocyte Shire
GlaxoSmithKline Sunovion
GileadSciences Theravance
Grünenthal
Chiltern
Covance
ICON
INCResearch
PPD
PRA
![Page 12: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/12.jpg)
12
Sponsorrespondentsrepresentedcompaniesofvaryingsize,whileCROrespondentswerecomprisedofLargeandMid-sizedCROs.AmajorityofrespondentsfrombothSponsorsandCROsrepresentedcompaniesheadquarteredintheUnitedStates,withtheremainderprimarilyinWesternEurope.
CharacteristicsofAQCMemberSample:CompanySize&Location
78%
19%1%2% UnitedStates
WesternEurope
Japan
Other
Sponsors CROs
41%
15%17%
26%1%
Top20Biopharma($10+Bsales)Top50/Mid-sizedBiopharma($1.0-$9.9Bsales)OtherMid-sizedBiopharma($500-$999Msales)Small/SpecialtyBiopharma(<$500Msales)Other
71%
27%2% UnitedStates
WesternEurope
Japan
Other
67%
33%
LargeCRO($1+Brevenue)
Mid-sizedCRO($100-$999Mrevenue)
Small/SpecialtyCRO(<$100Mrevenue)
Other
N=103
N=103
N=84
N=84
![Page 13: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/13.jpg)
13
ThesamplewaslargelycomposedofrespondentsrepresentingtheClinicalDevelopment/Operationsfunctionoftheirorganizations,followedbyQualityAssurance/QualityControl.
CharacteristicsofAQCMemberSample:RespondentRoles
Sponsors CROs
54%
16%
3%
18%7%
ClinicalDevelopment/Operations
Procurement/Outsourcing/VendorManagementRegulatoryAffairs
Medical/Scientific
ExecutiveManagement
QualityAssurance/QualityControl
Other
52%
12%4%7%
19%6%
ClinicalDevelopment/Operations
BusinessDevelopment
AllianceManagement/Partnerships
Medical/Scientific/Regulatory
ExecutiveManagement
QualityAssurance/QualityControl
Other
N=102 N=84
![Page 14: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/14.jpg)
14
ApproximatelyhalfofrespondentsfromSponsororganizationsindicatedthattheyutilizeamixoffull-serviceandfunctionaloutsourcingforclinicaldevelopment,followedbyprimarilyusingafunctionalproviderandprimarilyutilizingafull-serviceapproach.
CharacteristicsofAQCMemberSample:OutsourcingModels
19%
23%58%
Primarily(>80%)full-serviceoutsourcing
Primarily(>80%)functionaloutsourcing
Mixoffull-serviceandfunctionaloutsourcing
Sponsors’OutsourcingModels
N=103
![Page 15: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/15.jpg)
15
PatientViewsonUnderstandingof
theirConditionsbyHealthcareProviders
![Page 16: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/16.jpg)
16
Onaverage,patientswerenotveryimpressedwiththeirhealthcareproviders’understandingofwhatit’sliketobeapatientwiththeirconditions.Meansinthissectionofthesurveyrangedfrom2.9to3.4onascaleof1(understandsnotatall)to5(understandsverywell),andforeachquestion,between26%and39%ofpatientsgavearatingof1or2.
PatientViewsonUnderstandingoftheirConditionsbyProviders
Scaleof1(notatall)to5(verywell).Ifyouseemorethanonehealthcareproviderforyourcondition,andifyouropinionsregardingthemaredifferent,pleaserespondforthehealthcareproviderwhoyouseemostoften.
11%
12%
11%
14%
12%
11%
13%
16%
15%
15%
16%
14%
16%
18%
17%
17%
22%
22%
21%
22%
23%
25%
23%
24%
26%
26%
26%
26%
26%
23%
22%
18%
27%
26%
27%
25%
23%
23%
25%
25%
What’smostimportanttoyouinatreatment
Thesymptomsthatbotheryouthemost
Allofthedifferentkindsofsymptoms
Whatsideeffectsyouexperience
Typeofpain/discomfort
Amountofpain/discomfort
Whatyouworryaboutinatreatment
Worklifeandabilitytomakealiving
1- Notatall 2 3 4 5- Verywell
Mean N
3.4 497
3.4 515
3.4 512
3.3 501
3.3 486
3.3 493
3.3 493
3.2 445
Howwelldoyoubelievethatyourdoctor(s)andnurse(s)understandwhatit’sliketobeapatientwithyourcondition,ineachofthefollowingways?
Slide1of2
![Page 17: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/17.jpg)
17
Patientswereonaveragemostlikelytofeelthattheirprovidersunderstoodtheirsymptomsandtreatmentpreferences,butwerelesslikelytoperceivethattheirprovidersunderstoodtheimpactsoftheirconditionsontheirlivesandparticularlyontheirfamilyrelationshipsandabilitytocareforchildren.
PatientViewsonUnderstandingoftheirConditionsbyProviders
15%
17%
14%
20%
17%
20%
19%
24%
19%
15%
18%
17%
20%
19%
19%
14%
22%
25%
26%
18%
21%
20%
24%
28%
24%
23%
24%
17%
18%
21%
19%
20%
20%
20%
18%
27%
23%
21%
19%
15%
Howyourothermedicalconditions(besidesthisone)affectyou
Abilitytoperformbasictasksofliving(hygiene,housework,etc.)
Abilitytotakepartinactivitieswithfriendsandinthecommunity
Howthecostaffectsyou
Howtheinconvenienceordiscomfortaffectsyou
Mentalhealth/emotionalstate(e.g.Happiness,worry,stress)
Relationshipwithyourspouse/partner
Relationshipwithandabilitytocareforyourchildren
1- Notatall 2 3 4 5- Verywell
Howwelldoyoubelievethatyourdoctor(s)andnurse(s)understandwhatit’sliketobeapatientwithyourcondition,ineachofthefollowingways?
Slide2of2
Scaleof1(notatall)to5(verywell).Ifyouseemorethanonehealthcareproviderforyourcondition,andifyouropinionsregardingthemaredifferent,pleaserespondforthehealthcareproviderwhoyouseemostoften.
Mean N
3.2 470
3.2 497
3.1 497
3.1 487
3.1 503
3.0 511
3.0 370
2.9 255
![Page 18: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/18.jpg)
18
ThemesinOpen-EndedCommentsPatientViewsonUnderstandingoftheirConditionsbyProviders
• No-onecanrelatetopain/fatigue/symptomslikethis,andtheirimpacts,unlesstheyhaveexperienceditthemselves
• Lackof“vocabulary”and/orself-trackingtoappropriatelyconveyexperiencetoproviders
• Providersaretoobusytotrytounderstandallofthesethings
– Briefvisitsforcepatientstoconveyonly“1or2topsymptoms;”focuson“abilitytoworkformoney”concernsatexpenseof“abilitytoplay”orfamilyconcerns
• Notproviders’jobtounderstandthesethings,notpartofmedicine
• Prescribingpatternsdonottakeintoaccountpatientpreferencesre.tradingasymptomforasideeffectorrisk;donothonortreatmentrefusals
• Doctorsfailtotrackcharts/histories,onlygrasp“what’sgoingonnow”
• Specialistcaremeansthateachdoctoronlyunderstandsonepartofthepatient
• Patientspurposefullydon’tsharethisinformation(seelaterslides)
• Prescribingpatterns(tests,treatments,referrals)demonstratefailuretounderstandlogisticsandstressofgettingcare,i.e.transportationconcerns,financialconcerns,insurancehassles,timeoffofwork
![Page 19: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/19.jpg)
19
Onaverage,patientswithchronicconditionsfeltmostunderstoodbytheirproviders.Thosewithdegenerativeconditionsfeltleastunderstoodwhenitcametomostaspectsofdisease,butthosewithepisodicconditionsfeltleastunderstoodwithrespecttoimpactsontheirrelationshipsandabilitytofunctionatwork,athome,andinthecommunity.
PatientViewsonUnderstandingbyProviders:ByTypeofCondition
Meanratingsofperceivedunderstandingonascaleof1(notatall)to5(verywell)
Chronicbutstable Degenerative Episodic
What’smostimportanttoyouinatreatment 3.6 3.2 3.3Thesymptomsthatbotheryouthemost* 3.5 3.3 3.4Allofthedifferentkindsofsymptoms 3.5 3.2 3.4Whatsideeffectsyouexperience 3.4 3.2 3.5Typeofpain/discomfort* 3.4 3.1 3.2Amountofpain/discomfort 3.4 3.2 3.3Whatyouworryaboutinatreatment 3.4 3.2 3.2Worklifeandabilitytomakealiving* 3.3 3.2 2.7Howyourothermedicalconditions(besidesthisone)affectyou 3.3 3.0 3.1Abilitytoperformbasictasksofliving(hygiene,housework,etc.)* 3.2 3.2 2.9Abilitytotakepartinactivitieswithfriendsandinthecommunity 3.2 3.2 2.9Howthecostaffectsyou 3.2 3.1 3.2Howtheinconvenienceordiscomfortaffectsyou 3.1 3.0 3.2Mentalhealth/emotionalstate(e.g.Happiness,worry,stress) 3.1 3.1 3.1Relationshipwithyourspouse/partner 3.1 2.9 2.7Relationshipwithandabilitytocareforyourchildren* 3.0 3.0 2.3
Nrange= 149-299 70-152 25-47
PerceptionsofDoctors’andNurses’UnderstandingofPatientExperiencebyTypeofMedicalCondition(onlycategorieswithN>10)
Note:Highestmeanperrowhighlightedinyellow,lowestinred;*p<.05(unadjustedformultipletests)
![Page 20: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/20.jpg)
20
Meanratingsofperceivedunderstandingonascaleof1(notatall)to5(verywell) Severe Moderate Mild Itvaries None
What’smostimportanttoyouinatreatment 3.3 3.4 3.8 3.6 3.2Thesymptomsthatbotheryouthemost** 3.2 3.4 3.8 3.5 3.2Allofthedifferentkindsofsymptoms** 3.2 3.4 3.9 3.3 3.3Whatsideeffectsyouexperience 3.3 3.3 3.6 3.3 3.2Typeofpain/discomfort 3.2 3.3 3.6 3.4 2.9Amountofpain/discomfort* 3.1 3.3 3.7 3.3 3.0Whatyouworryaboutinatreatment 3.2 3.2 3.5 3.4 3.0Worklifeandabilitytomakealiving 3.3 3.1 3.2 3.0 2.8Howyourothermedicalconditions(besidesthisone)affectyou 3.0 3.2 3.4 3.1 3.2Abilitytoperformbasictasksofliving(hygiene,housework,etc.) 3.1 3.2 3.3 3.2 2.6Abilitytotakepartinactivitieswithfriendsandinthecommunity 3.2 3.1 3.2 3.1 2.7Howthecostaffectsyou 3.1 3.0 3.4 3.2 3.2Howtheinconvenienceordiscomfortaffectsyou 3.0 3.0 3.4 3.1 3.0Mentalhealth/emotionalstate(e.g.Happiness,worry,stress) 3.0 3.0 3.2 3.1 2.7Relationshipwithyourspouse/partner 3.0 2.9 3.4 2.9 2.6Relationshipwithandabilitytocareforyourchildren 2.9 2.9 2.9 3.1 2.4
Nrange= 77-159 87-181 37-80 35-63 18-35
PerceptionsofDoctors’andNurses’UnderstandingofPatientExperiencebyImpactofMedicalCondition
Onaverage,patientswithmilddiseaseimpactsfeltmostunderstoodbytheirproviders.Thoseattheextremesofthespectrum– withnoimpactorwithsevereimpact– feltleastunderstoodwhenitcametomostaspectsofdisease.
PatientViewsonUnderstandingbyProviders:ByImpactofCondition
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01(unadjustedformultipletests)
![Page 21: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/21.jpg)
21
Patientswithhigh“touchrates”withtheirdoctorswerenomorelikelytofeelunderstoodthanwerepatientswithlessfrequentcontact.
PatientViewsonUnderstandingbyProviders:ByFrequencyofCare
Meanratingsofperceivedunderstandingonascaleof1(notatall)to5(verywell)
Morethan12timesperyear
5to12times
peryear
2to4times
peryear
Onceperyearorless
Itdepends
What’smostimportanttoyouinatreatment 3.1 3.4 3.5 3.4 3.5Thesymptomsthatbotheryouthemost 3.4 3.2 3.5 3.4 3.4Allofthedifferentkindsofsymptoms* 3.4 3.1 3.6 3.5 3.3Whatsideeffectsyouexperience 3.2 3.3 3.5 3.1 3.4Typeofpain/discomfort 3.3 3.2 3.4 3.3 3.2Amountofpain/discomfort 3.3 3.2 3.4 3.3 3.2Whatyouworryaboutinatreatment 3.1 3.3 3.4 3.0 3.5Worklifeandabilitytomakealiving 3.4 3.2 3.2 3.1 3.0Howyourothermedicalconditions(besidesthisone)affectyou 3.2 3.0 3.2 3.3 3.1Abilitytoperformbasictasksofliving(hygiene,housework,etc.) 3.0 3.1 3.2 3.3 3.0Abilitytotakepartinactivitieswithfriendsandinthecommunity 3.1 3.1 3.2 3.0 3.1Howthecostaffectsyou 2.7 3.1 3.3 3.0 3.0Howtheinconvenienceordiscomfortaffectsyou 3.0 3.1 3.1 3.0 3.1Mentalhealth/emotionalstate(e.g.Happiness,worry,stress) 3.1 2.8 3.1 3.1 2.9Relationshipwithyourspouse/partner 3.0 2.9 3.1 2.8 2.8Relationshipwithandabilitytocareforyourchildren 2.9 2.9 2.9 2.8 2.8
Nrange= 34-53 52-104 116-251 25-60 27-53
PerceptionsofDoctors’andNurses’UnderstandingofPatientExperiencebyFrequencyofCare
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01(unadjustedformultipletests)
![Page 22: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/22.jpg)
22
Patientswhowererelieduponbyfamilymembersfordirectcareand/orfinancialsupportwerelesslikelythanotherstofeelwell-understoodbytheirmedicalcareproviders,whenitcametonearlyeveryaspectoftheirconditionsandlives.
PatientViewsonUnderstandingbyProviders:ByFamilyResponsibility
Meanratingsofperceivedunderstandingonascaleof1(notatall)to5(verywell)
Yes (providescareorfinancial supporttofamilymembers)
No
What’smostimportanttoyouinatreatment 3.4 3.5Thesymptomsthatbotheryouthemost*** 3.2 3.6Allofthedifferentkindsofsymptoms*** 3.2 3.6Whatsideeffectsyouexperience 3.2 3.4Typeofpain/discomfort** 3.1 3.4Amountofpain/discomfort** 3.1 3.4Whatyouworryaboutinatreatment 3.2 3.3Worklifeandabilitytomakealiving 3.2 3.2Howyourothermedicalconditions(besidesthisone)affectyou** 3.0 3.3Abilitytoperformbasictasksofliving(hygiene,housework,etc.) 3.1 3.2Abilitytotakepartinactivitieswithfriendsandinthecommunity 3.1 3.2Howthecostaffectsyou 3.1 3.2Howtheinconvenienceordiscomfortaffectsyou 3.0 3.2Mentalhealth/emotionalstate(e.g.Happiness,worry,stress) 2.9 3.1Relationshipwithyourspouse/partner 3.0 3.0Relationshipwithandabilitytocareforyourchildren 2.8 2.9
Nrange= 144-217 110-297
PerceptionsofDoctors’andNurses’UnderstandingofPatientExperiencebyFamilyResponsibility
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005(unadjustedformultipletests)
![Page 23: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/23.jpg)
23
Employedpatientswerelesslikelythanotherstofeelthatthefunctionalaspectsoftheirconditionswerewell-understoodbytheirproviders.Thosewhoworkedfull-timewereleastlikelytofeelthatthecost,theinconvenience,andotherworriesabouttreatmentswerewell-understood.Unemployedpatientswereleastlikelytofeelthattheirpain/discomfortandothersymptomswerewell-understood.
PatientViewsonUnderstandingbyProviders:ByEmploymentStatus
Meanratingsofperceivedunderstandingonascaleof1(notatall)to5(verywell) Fulltime Parttime Retired No
What’smostimportanttoyouinatreatment 3.4 3.6 3.5 3.4Thesymptomsthatbotheryouthemost 3.4 3.4 3.5 3.3Allofthedifferentkindsofsymptoms 3.5 3.5 3.5 3.3Whatsideeffectsyouexperience 3.4 3.6 3.2 3.4Typeofpain/discomfort 3.3 3.5 3.4 3.2Amountofpain/discomfort 3.4 3.3 3.4 3.1Whatyouworryaboutinatreatment 3.1 3.3 3.3 3.4Worklifeandabilitytomakealiving 3.0 3.0 3.2 3.4Howyourothermedicalconditions(besidesthisone)affectyou 3.4 3.1 3.2 3.0Abilitytoperformbasictasksofliving(hygiene,housework,etc.) 3.1 3.1 3.2 3.2Abilitytotakepartinactivitieswithfriendsandinthecommunity 3.0 3.0 3.2 3.2Howthecostaffectsyou 3.0 3.2 3.2 3.2Howtheinconvenienceordiscomfortaffectsyou 3.0 3.1 3.2 3.1Mentalhealth/emotionalstate(e.g.Happiness,worry,stress) 3.0 2.9 3.0 3.2Relationshipwithyourspouse/partner 2.9 3.0 3.0 3.1Relationshipwithandabilitytocareforyourchildren 2.9 3.0 2.7 3.0
Nrange= 69-131 35-64 62-154 88-171
PerceptionsofDoctors’andNurses’UnderstandingofPatientExperiencebyCurrentEmployment
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01(unadjustedformultipletests)
![Page 24: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/24.jpg)
24
Patientswhohadparticipatedinclinicaltrialsweremorelikelythanotherstofeelwell-understoodbytheirmedicalcareproviderswhenitcametonearlyeveryaspectoftheirconditionsandlives,theonlyexceptionsbeingtheimpactsoftheirconditionsonfamilyrelationships.
PatientViewsonUnderstandingbyProviders:ByHistoryofTrialParticipation
Meanratingsofperceivedunderstandingonascaleof1(notatall)to5(verywell) Yes No
What’smostimportanttoyouinatreatment 3.6 3.3Thesymptomsthatbotheryouthemost* 3.5 3.3Allofthedifferentkindsofsymptoms* 3.6 3.3Whatsideeffectsyouexperience* 3.5 3.2Typeofpain/discomfort 3.4 3.2Amountofpain/discomfort* 3.4 3.2Whatyouworryaboutinatreatment 3.4 3.2Worklifeandabilitytomakealiving 3.3 3.1Howyourothermedicalconditions(besidesthisone)affectyou 3.2 3.1Abilitytoperformbasictasksofliving(hygiene,housework,etc.) 3.3 3.1Abilitytotakepartinactivitieswithfriendsandinthecommunity 3.2 3.1Howthecostaffectsyou 3.2 3.1Howtheinconvenienceordiscomfortaffectsyou 3.2 3.0Mentalhealth/emotionalstate(e.g.Happiness,worry,stress) 3.1 3.0Relationshipwithyourspouse/partner 3.0 3.0Relationshipwithandabilitytocareforyourchildren 2.9 2.9
Nrange= 92-214 163-302
PerceptionsofDoctors’andNurses’UnderstandingofPatientExperiencebyHaveEverParticipatedinaClinicalTrial
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01(unadjustedformultipletests)
![Page 25: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/25.jpg)
25
Olderpatientsweremostlikelytofeelwell-understoodbytheirmedicalcareproviderswhenitcametonearlyeveryaspectoftheirconditions,theexceptionbeingthesideeffectsoftreatments(theNforthe76+agegroupwassmall,butthetrendoftenextendedtothe61-75agegroup).Patientsbetweenages31-45wereleastlikelytofeelunderstood.Thesetrendsmayrelatetothoseshowninpreviousslidesregardingtypesofconditionsexperienced,employmentstatus,familyresponsibilities,etc.
PatientViewsonUnderstandingbyProviders:ByAgeGroup
Meanratingsofperceivedunderstandingonascaleof1(notatall)to5(verywell) 76+ 61-75 46-60 31-45 18-30
What’smostimportanttoyouinatreatment 4.0 3.5 3.4 3.2 3.5Thesymptomsthatbotheryouthemost** 4.0 3.6 3.4 2.9 3.4Allofthedifferentkindsofsymptoms*** 3.9 3.6 3.4 2.9 3.6Whatsideeffectsyouexperience 3.5 3.4 3.4 3.1 3.8Typeofpain/discomfort* 3.8 3.5 3.2 2.9 3.5Amountofpain/discomfort** 3.8 3.5 3.2 2.9 3.2Whatyouworryaboutinatreatment* 4.1 3.4 3.3 3.0 3.3Worklifeandabilitytomakealiving 3.8 3.2 3.3 2.9 2.9Howyourothermedicalconditions(besidesthisone)affectyou 3.3 3.3 3.2 3.0 2.9Abilitytoperformbasictasksofliving(hygiene,housework,etc.)** 3.5 3.3 3.2 2.6 3.2Abilitytotakepartinactivitieswithfriendsandinthecommunity* 3.3 3.3 3.1 2.7 3.1Howthecostaffectsyou** 3.8 3.3 3.0 2.6 3.4Howtheinconvenienceordiscomfortaffectsyou 3.4 3.2 3.0 2.8 3.1Mentalhealth/emotionalstate(e.g.Happiness,worry,stress) 3.5 3.2 3.1 2.7 3.2Relationshipwithyourspouse/partner 3.5 3.1 3.0 2.6 3.2Relationshipwithandabilitytocareforyourchildren 4.0 2.9 2.9 2.5 3.7
Nrange= 5-18 78-185 96-183 44-71 6-14
PerceptionsofDoctors’andNurses’UnderstandingofPatientExperiencebyAge
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005(unadjustedformultipletests)
![Page 26: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/26.jpg)
26
Whenitcametosymptoms,particularlypain,femalesonaveragefeltlessunderstoodbymedicalcareprovidersthandidmales.Thiswasalsotruefortreatmentpreferencesandforimpactsonbasictasksofdailylivingandrelationships,althoughthedifferencesintheseareasweresmaller.Malesfeltslightlylessunderstoodthanfemaleswhenitcametoimpactsonworklifeandsideeffects.
PatientViewsonUnderstandingbyProviders:BySex
Meanratingsofperceivedunderstandingonascaleof1(notatall)to5(verywell) Female Male
What’smostimportanttoyouinatreatment 3.4 3.6Thesymptomsthatbotheryouthemost 3.4 3.6Allofthedifferentkindsofsymptoms* 3.3 3.6Whatsideeffectsyouexperience 3.4 3.3Typeofpain/discomfort 3.2 3.5Amountofpain/discomfort 3.2 3.5Whatyouworryaboutinatreatment 3.3 3.3Worklifeandabilitytomakealiving 3.2 3.1Howyourothermedicalconditions(besidesthisone)affectyou 3.1 3.3Abilitytoperformbasictasksofliving(hygiene,housework,etc.) 3.1 3.2Abilitytotakepartinactivitieswithfriendsandinthecommunity 3.1 3.1Howthecostaffectsyou 3.1 3.1Howtheinconvenienceordiscomfortaffectsyou 3.1 3.1Mentalhealth/emotionalstate(e.g.Happiness,worry,stress) 3.0 3.1Relationshipwithyourspouse/partner 2.9 3.0Relationshipwithandabilitytocareforyourchildren 2.8 2.9
Nrange= 167-340 59-121
PerceptionsofDoctors’andNurses’UnderstandingofPatientExperiencebySex
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005(unadjustedformultipletests)
![Page 27: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/27.jpg)
27
Ingeneral,patientswhoaresingleormarried/partneredfeelmostunderstoodbytheirmedicalcareproviders,whereasthosewhoaredivorced/separated,orparticularlywidowed,feelleastunderstood.Thedifferencesacrossgroupswereagainmorepronouncedforimpactsonrelationshipsthanforthemoreclinicalaspectsofthecondition.
PatientViewsonUnderstandingbyProviders:ByMaritalStatus
Meanratingsofperceivedunderstandingonascaleof1(notatall)to5(verywell)
Married/domesticpartner
Divorced/separated Single Widow/
widower
What’smostimportanttoyouinatreatment 3.5 3.3 3.6 3.3Thesymptomsthatbotheryouthemost 3.5 3.3 3.5 3.0Allofthedifferentkindsofsymptoms 3.5 3.3 3.5 3.0Whatsideeffectsyouexperience 3.4 3.3 3.5 3.1Typeofpain/discomfort 3.4 3.1 3.5 3.1Amountofpain/discomfort 3.4 3.1 3.4 3.0Whatyouworryaboutinatreatment 3.3 3.2 3.4 3.3Worklifeandabilitytomakealiving 3.2 3.0 3.3 3.4Howyourothermedicalconditions(besidesthisone)affectyou* 3.3 2.9 3.3 2.7Abilitytoperformbasictasksofliving(hygiene,housework,etc.) 3.2 3.1 3.3 2.8Abilitytotakepartinactivitieswithfriendsandinthecommunity 3.2 3.1 3.2 2.8Howthecostaffectsyou 3.2 2.9 3.1 3.0Howtheinconvenienceordiscomfortaffectsyou 3.2 2.8 3.3 2.8Mentalhealth/emotionalstate(e.g.Happiness,worry,stress) 3.1 3.0 3.1 2.8Relationshipwithyourspouse/partner 3.1 2.8 3.0 2.3Relationshipwithandabilitytocareforyourchildren 2.8 2.9 3.1 2.1
Nrange= 129-249 49-101 36-86 8-31
PerceptionsofDoctors’andNurses’UnderstandingofPatientExperiencebyMaritalStatus
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005(unadjustedformultipletests)
![Page 28: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/28.jpg)
28
Ingeneral,therewasatrendtowardaninverserelationshipbetweeneducationalattainmentandperceptionsofunderstanding.Thismayreflectpatternsofcarereceived(i.e.,ruralone-doctorvs.urbanmulti-doctor,migrationpatternsoverlifetime,etc.)and/orthetrustplacedinproviders.
PatientViewsonUnderstandingbyProviders:ByEducationalAttainment
Meanratingsofperceivedunderstandingonascaleof1(notatall)to5(verywell)
Advanceddegree
Completedcollegedegree
Somecollege
Completedhighschool
What’smostimportanttoyouinatreatment 3.4 3.4 3.4 3.4Thesymptomsthatbotheryouthemost 3.3 3.5 3.4 3.5Allofthedifferentkindsofsymptoms 3.4 3.6 3.4 3.2Whatsideeffectsyouexperience 3.4 3.3 3.3 3.5Typeofpain/discomfort 3.3 3.4 3.2 3.4Amountofpain/discomfort 3.3 3.4 3.2 3.4Whatyouworryaboutinatreatment* 3.2 3.2 3.3 3.6Worklifeandabilitytomakealiving 3.1 3.3 3.1 3.3Howyourothermedicalconditions(besidesthisone)affectyou 3.1 3.3 3.1 3.3Abilitytoperformbasictasksofliving(hygiene,housework,etc.) 3.2 3.1 3.1 3.3Abilitytotakepartinactivitieswithfriendsandinthecommunity 3.0 3.0 3.2 3.3Howthecostaffectsyou 3.1 3.0 3.2 3.1Howtheinconvenienceordiscomfortaffectsyou 2.9 3.1 3.1 3.2Mentalhealth/emotionalstate(e.g.Happiness,worry,stress) 2.9 3.1 3.0 3.2Relationshipwithyourspouse/partner 3.0 2.8 3.1 3.1Relationshipwithandabilitytocareforyourchildren 2.7 2.7 3.1 2.8
Nrange= 52-110 81-154 70-149 23-52
PerceptionsofDoctors’andNurses’UnderstandingofPatientExperiencebyHighestLevelofEducation(onlycategorieswithN>10)
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005(unadjustedformultipletests)
![Page 29: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/29.jpg)
29
Ingeneral,patientsresidingintheWesternUS/MountainareasfeltlessunderstoodthandidthoseintheMidwestorEasternregions,exceptregardingtheimpactsoftheirconditionsontheirabilitytowork.Regionaldifferenceswereparticularlypronouncedforimpactsonrelationships(bothfamilyandcommunity),asopposedtoclinicalaspectsofthediseasesuchassymptoms/painandabilitytoperformbasictasksofdailyliving,possiblyreflectingculturaldifferencesincommunication.
PatientViewsonUnderstandingbyProviders:ByGeographicRegion
Meanratingsofperceivedunderstandingonascaleof1(notatall)to5(verywell)
West,Southwest Mountain Midwest Northeast Southeast
What’smostimportanttoyouinatreatment 3.3 3.3 3.4 3.6 3.4Thesymptomsthatbotheryouthemost 3.2 3.5 3.5 3.4 3.5Allofthedifferentkindsofsymptoms 3.2 3.2 3.4 3.5 3.5Whatsideeffectsyouexperience 3.2 2.8 3.5 3.4 3.4Typeofpain/discomfort 3.1 3.2 3.2 3.4 3.4Amountofpain/discomfort 3.2 3.2 3.2 3.3 3.4Whatyouworryaboutinatreatment 3.1 3.1 3.4 3.3 3.3Worklifeandabilitytomakealiving 3.1 3.5 3.4 3.0 3.2Howyourothermedicalconditions(besidesthisone)affectyou 2.9 3.6 3.1 3.2 3.3Abilitytoperformbasictasksofliving(hygiene,housework,etc.) 3.0 3.0 3.2 3.2 3.2Abilitytotakepartinactivitieswithfriendsandinthecommunity 3.0 2.6 3.3 2.9 3.2Howthecostaffectsyou 3.1 2.6 3.0 3.1 3.2Howtheinconvenienceordiscomfortaffectsyou 2.8 2.6 3.0 3.2 3.2Mentalhealth/emotionalstate(e.g.Happiness,worry,stress) 3.0 2.8 3.2 3.0 3.1Relationshipwithyourspouse/partner 2.9 2.5 3.2 2.7 3.1Relationshipwithandabilitytocareforyourchildren 2.7 2.2 3.0 2.8 2.9
Nrange= 36-63 5-16 33-62 51-95 100-227
PerceptionsofDoctors’andNurses’UnderstandingofPatientExperiencebyRegion
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005(unadjustedformultipletests)
![Page 30: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/30.jpg)
30
Patients:ArethereaspectsofhowyourconditionortreatmentaffectsyouthatyoudoNOTsharewithyourhealthcareproviders?
UnderstandingofPatientsbyProviders
28%
72%
Yes
No
N=498
![Page 31: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/31.jpg)
31
UnderstandingofPatientsbyProviders:ReasonsforNotSharing
• Embarrassment/shameintalkingaboute.g.disability,difficultywithpersonalorhomecare/hygiene,sexualorboweldysfunction,etc.
• Concernsregardingconfidentiality,notwantingittobecome“partofrecord”• Fearofe.g.gettingdriver’slicenserevoked,beingpreventedfromworking,beingusheredinto
“psychtrack”ofmedicalcare• Fearofbeingprescribedmedicationsthattheydon’twanttotake• Fearofhavingcurrentlyprescribedmedications“takenaway”• Emotionallydifficulttotalkaboutfears/anxieties,upsetting• Fearofjudgmentregardinge.g.dietaryhabits/weight,sexualhistory/lifestyle,substanceuse,etc.• Assumptionthatifhealthcareprovidersdon’taskaboutthesethings,thentheydon’tcare/not
partofjob;“medicineisaboutscience,notaboutlife”• Fearoftalkingaboutsomethingpersonalandmeaningfulandnotbeinglistenedto;feeling
unimportant,worthless• Perceptionofbeingrushedthroughmedicalvisits,notimetotalk• Previousexperiencewithtryingtotalktohealthcareprovidersaboutthesethingsandgetting
demeaning/uncaringresponsesà frustrationandhurt• Fearoflosingservicesiftheybecomelabeledas“difficult,”“refractory,”“time-consuming,”orat
riskforaddiction
![Page 32: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/32.jpg)
32
UnderstandingofPatientsbyProviders: DiseaseAspectsNotShared
• Painandpsychologicalimpactsthereof• Disability,inwork,self-care,careofothers(e.g.children,pets)• Emotionalimpactsofdisease,i.e.anxiety,fears
– “Itriedtotellhimandhesaidhewasn’tasocialworker.”• “Non-critical,”“non-medical”aspectsofdisease,i.e.inabilityto“havefun,”toperformparticular
self-careorchild-caretasks,etc.– “Someissuesarenotmedical…Iamhavingtroublebuttoningmyshirt.And,Ican’tbend
overtotieshoesanymore.Ican’treachmyfeettoputonsocks.”• Impactsonsexualityandrelationships• Implicationsoflifestyledecisionsondisease,i.e.diet,sexuallifestyle,useofalternative
therapies,etc.• Anyinformationthatcouldimpactprivileges/permissions,i.e.visualeffectsthatcouldimpact
driver’slicense,injuries/painthatcouldimpactpermissiontoreturntowork,cognitiveissuesthatcouldimpactindependentliving,etc.
• Bowelfunction• Addiction/dependence• Obesity-relatedissues• Financialaspectsofdiseaseand/ortreatment
![Page 33: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/33.jpg)
33
ConfidenceinInformationProvided
toClinicalTrialParticipants
![Page 34: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/34.jpg)
34
Mostpatientshadatleastafairlevelofconfidencethattrialparticipantsareinformedfullyandhonestlyabouttheclinicaltrialprocess.Patientsweremostlikelytobeconfidentininformationprovidedaboutrighttowithdraw,procedures,andpossiblebenefits,andweremostskepticalaboutinformationrelatingtotreatmentalternatives,risksandsideeffects,anddoctors’motivations.
Patients’ConfidenceinClinicalTrialParticipantInformation
3%
4%
3%
4%
7%
7%
6%
13%
9%
12%
8%
14%
7%
7%
9%
10%
11%
12%
14%
14%
16%
15%
17%
17%
19%
20%
19%
23%
17%
19%
25%
19%
23%
21%
25%
27%
19%
28%
29%
26%
24%
21%
28%
21%
26%
21%
25%
17%
51%
41%
40%
38%
41%
40%
27%
33%
25%
31%
24%
26%
Righttodropoutofthestudy
Typesofprocedurestobeperformed
Possiblebenefitsofstudytreatment
Overalltimecommitment
Howpersonalinformationwillbekeptprivate
Costsassociatedwithstudyparticipation
Painordiscomforttoexpect
Ifandhowpatientswillreceiveinformationaboutthestudy
Possiblerisksofstudytreatment
Doctor’smotivationsfordoingthestudy
Possiblesideeffectsofstudytreatment
Otherwaysofgettingtreatmentbesidesstudyparticipation
1- Notatallconfident 2 3 4 5- Veryconfident
Mean N4.1 399
3.9 439
3.9 433
3.8 447
3.8 434
3.7 418
3.6 422
3.5 420
3.4 436
3.4 411
3.4 436
3.3 386
Whenpatientsareapproachedaboutclinicaltrialsrunbypharmaceuticalcompanies,howconfidentdoyoufeelthattheyareinformedfullyandhonestlyabouteachofthefollowing?
![Page 35: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/35.jpg)
35
Typesofprocedures
Righttodropout
PossiblesideeffectsPossiblerisks
Possiblebenefits
Painordiscomfort
Privacyofpersonalinfo
Overalltimecommitment
Costs
Otherwaystogettreatment
Doctor'smotivations
Communicationofresults
3.0
3.5
4.0
4.5
5.0
3.0 3.5 4.0 4.5 5.0
Patie
nts
Sponsor/CROAQCMembers
BothpatientsandAQCMemberrespondentswerereasonablyconfidentinpatients’receiptofcompleteandhonestinformationabouttherighttowithdrawfromatrial,itsprocedures,anditspossiblebenefits,andbothwereskepticalaboutinformationregardingthecommunicationofresultsanddoctors’motivations.AQCMemberswerequiteconfidentinpatients’receiptofcompleteandhonestinformationaboutpossiblesideeffects,risks,anddiscomforts,butpatientswerelessso.
Patientvs.AQCMemberConfidenceinClinicalTrialInformation
Patients:N=386-447SponsorN=83-94,CRON=63-76Q:AsaSponsor/CROexecutingtrialsonbehalfofSponsors,howconfidentareyouthatpotentialclinicaltrialparticipantsarefullyandhonestlyinformedabouteachofthefollowing?
ConfidenceThatTrialParticipantsareInformedAbout…MeanRatings:1=NotAtAllConfidentto5=VeryConfident
![Page 36: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/36.jpg)
36
Muchofthepatient-sponsordifferenceinconfidencewasdrivenbypatientswithnoexperienceinclinicaltrials;patientswithclinicaltrialexperiencehadsubstantiallygreaterlevelsofconfidence– muchclosertothelevelsexhibitedbyAQCmembers– thandidthosewithnohistoryofclinicaltrialparticipation(thisslideandnext).
Patients:N=185to204SponsorN=83-94,CRON=63-76Q:AsaSponsor/CROexecutingtrialsonbehalfofSponsors,howconfidentareyouthatpotentialclinicaltrialparticipantsarefullyandhonestlyinformedabouteachofthefollowing?
ConfidenceThatTrialParticipantsareInformedAbout…MeanRatings:1=NotAtAllConfidentto5=VeryConfident
Typesofprocedures
Righttodropout
Possiblesideeffects
Possiblerisks
Possiblebenefits
Painordiscomfort
Privacyofpersonalinfo
Overalltimecommitment
Costs
Otherwaystoget
treatment
Doctor'smotivations
Communicationofresults
3.0
3.5
4.0
4.5
5.0
3.0 3.5 4.0 4.5 5.0
Patie
ntsw
ithClinicalTria
lHistory
Sponsor/CROAQCMembers
PatientswithClinicalTrialHistoryvs.AQCMemberConfidenceinClinicalTrialInformation
![Page 37: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/37.jpg)
37Patients:N=201to243SponsorN=83-94,CRON=63-76Q:AsaSponsor/CROexecutingtrialsonbehalfofSponsors,howconfidentareyouthatpotentialclinicaltrialparticipantsarefullyandhonestlyinformedabouteachofthefollowing?
Typesofprocedures
Righttodropout
PossiblesideeffectsPossiblerisks
Possiblebenefits
Painordiscomfort
Privacyofpersonalinfo
Overalltimecommitment
Costs
Otherwaystogettreatment
Doctor'smotivations
Communicationofresults
3.0
3.5
4.0
4.5
5.0
3.0 3.5 4.0 4.5 5.0
Patie
ntsw
ithou
tClinicalTria
lHistory
Sponsor/CROAQCMembers
ConfidenceThatTrialParticipantsareInformedAbout…MeanRatings:1=NotAtAllConfidentto5=VeryConfident
PatientswithoutClinicalTrialHistoryvs.AQCMemberConfidenceinClinicalTrialInformation
![Page 38: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/38.jpg)
38
Meanratingsonascaleof1(notatallconfident)to5(veryconfident)
Chronicbutstable Degenerative Episodic
Righttodropoutofthestudy 4.1 4.0 3.9
Typesofprocedurestobeperformed 4.0 3.8 3.8
Possiblebenefitsofstudytreatment 3.9 3.9 3.8
Overalltimecommitment 3.9 3.8 3.7
Howpersonalinformationwillbekeptprivate 3.9 3.8 3.7
Costsassociatedwithstudyparticipation 3.8 3.7 3.5
Painordiscomforttoexpect* 3.7 3.4 3.6
Ifandhowpatientswillreceiveinformationaboutthestudy,includingtheirpersonalresults* 3.6 3.4 2.9
Possiblerisksofstudytreatment 3.5 3.4 3.1
Doctor’smotivationsfordoingthestudy 3.6 3.3 3.1
Possiblesideeffectsofstudytreatment* 3.5 3.3 3.1
Otherwaysofgettingtreatmentbesidesstudyparticipation* 3.4 3.0 3.2
Nrange= 228-260 112-130 36-44
Patientswithchronicconditionswereonaveragemoreconfidentthanothersintheinformationprovidedtoclinicaltrialparticipants,andthosewithepisodicconditionsweregenerallyleastconfident.
Patients’ConfidenceinClinicalTrialInformation:ByTypeofCondition
ConfidencethatStudyPatientsareFullyandHonestlyInformedbyTypeofMedicalCondition(onlycategorieswithN>10)
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005(unadjustedformultipletests)
![Page 39: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/39.jpg)
39
Patientswithmildconditionswereonaveragemoreconfidentthanothersintheinformationprovidedtoclinicaltrialparticipants.
Patients’ConfidenceinClinicalTrialInformation:ByImpactofCondition
Meanratingsonascaleof1(notatallconfident)to5(veryconfident) Severe Moderate Mild Itvaries None
Righttodropoutofthestudy 4.1 4.0 4.3 4.3 3.8
Typesofprocedurestobeperformed 3.9 4.0 4.2 3.8 3.6
Possiblebenefitsofstudytreatment 4.0 3.8 4.2 3.9 4.0
Overalltimecommitment 3.9 3.7 4.1 3.7 3.9
Howpersonalinformationwillbekeptprivate* 3.8 3.6 4.3 3.8 3.7
Costsassociatedwithstudyparticipation* 3.7 3.6 4.2 3.6 3.6
Painordiscomforttoexpect 3.5 3.5 3.9 3.5 3.7
Ifandhowpatientswillreceiveinformationaboutthestudy,includingtheirpersonalresults 3.4 3.4 3.7 3.4 3.6
Possiblerisksofstudytreatment* 3.3 3.3 3.9 3.3 3.6
Doctor’smotivationsfordoingthestudy 3.4 3.3 3.7 3.3 3.8
Possiblesideeffectsofstudytreatment* 3.4 3.2 3.8 3.3 3.7
Otherwaysofgettingtreatmentbesidesstudyparticipation*** 3.0 3.1 3.9 3.5 3.5
Nrange= 113-135 142-156 64-75 42-56 22-29
ConfidencethatStudyPatientsareFullyandHonestlyInformedbyImpactofMedicalCondition
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005(unadjustedformultipletests)
![Page 40: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/40.jpg)
40
Therewasageneraltrendwherebypatientswhoseetheirphysiciansfrequentlymaybemoreskepticalabouttheinformationprovidedtoclinicaltrialparticipantsthanwerepatientswhoseetheirphysicianslessoften.
Patients’ConfidenceinClinicalTrialInformation:ByFrequencyofCare
Meanratingsonascaleof1(notatallconfident)to5(veryconfident)
Morethan12timesperyear
5to12timesperyear
2to4times
peryear
Onceperyearorless
Itdepends
Righttodropoutofthestudy 3.8 4.0 4.1 3.9 4.2
Typesofprocedurestobeperformed* 3.8 3.6 4.1 4.0 4.0
Possiblebenefitsofstudytreatment 4.0 3.8 4.0 4.0 4.0
Overalltimecommitment 3.8 3.8 3.8 4.1 3.8
Howpersonalinformationwillbekeptprivate 3.5 3.7 3.9 3.7 4.1
Costsassociatedwithstudyparticipation 3.8 3.6 3.9 3.5 3.7
Painordiscomforttoexpect* 3.6 3.2 3.6 3.9 3.7
Ifandhowpatientswillreceiveinformationaboutthestudy,includingtheirpersonalresults 3.2 3.3 3.6 3.4 3.7
Possiblerisksofstudytreatment 3.4 3.1 3.5 3.5 3.7
Doctor’smotivationsfordoingthestudy 3.4 3.4 3.5 3.4 3.6
Possiblesideeffectsofstudytreatment 3.4 3.1 3.5 3.5 3.5
Otherwaysofgettingtreatmentbesidesstudyparticipation 3.1 3.0 3.3 3.5 3.4Nrange= 37-43 70-83 191-224 43-49 37-48
ConfidencethatStudyPatientsareFullyandHonestlyInformedbyFrequencyofCare
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005(unadjustedformultipletests)
![Page 41: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/41.jpg)
41
Patientswhohadactuallyparticipatedinclinicaltrialsweremoreconfidentinthehonestyandcompletenessofinformationprovidedtotrialparticipantsthanwerepatientswhohadnot,ineveryareaexceptforone:howpatientswouldreceivestudyresults,includingpersonalresults.Evenamongpriortrialparticipants,however,confidencewasnotstronginsomeareas.
Patients’ConfidenceinClinicalTrialInformation:ByHistoryofTrialParticipation
Meanratingsonascaleof1(notatallconfident)to5(veryconfident) Yes No
Righttodropoutofthestudy*** 4.3 3.9
Typesofprocedurestobeperformed**** 4.2 3.8
Possiblebenefitsofstudytreatment 4.0 3.9
Overalltimecommitment** 4.0 3.7
Howpersonalinformationwillbekeptprivate 3.9 3.7
Costsassociatedwithstudyparticipation* 3.9 3.6
Painordiscomforttoexpect 3.7 3.5
Ifandhowpatientswillreceiveinformationaboutthestudy,includingtheirpersonalresults 3.5 3.5
Possiblerisksofstudytreatment** 3.6 3.3
Doctor’smotivationsfordoingthestudy* 3.6 3.3
Possiblesideeffectsofstudytreatment* 3.5 3.3
Otherwaysofgettingtreatmentbesidesstudyparticipation 3.4 3.1
Nrange= 185-204 201-243
ConfidencethatStudyPatientsareFullyandHonestlyInformedbyHistoryofTrialParticipation
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005;****p=.0001(unadjustedformultipletests)
![Page 42: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/42.jpg)
42
Ingeneral,patientsbetween31and60yearsofagewerelessconfidentinthehonestyandcompletenessofinformationprovidedtotrialparticipantsthanwereyoungerorolderpatients.
Patients’ConfidenceinClinicalTrialInformation:ByAgeGroup
Meanratingsonascaleof1(notatallconfident)to5(veryconfident) 76+ 61-75 46-60 31-45 18-30
Righttodropoutofthestudy 4.2 4.2 4.0 3.9 4.1
Typesofprocedurestobeperformed 4.2 4.1 3.8 3.7 3.7
Possiblebenefitsofstudytreatment 3.9 4.0 3.9 3.8 4.2
Overalltimecommitment 4.1 4.0 3.7 3.7 4.0
Howpersonalinformationwillbekeptprivate 4.0 3.9 3.8 3.6 4.0
Costsassociatedwithstudyparticipation* 4.3 4.0 3.5 3.5 3.9
Painordiscomforttoexpect* 3.8 3.8 3.5 3.2 4.1
Ifandhowpatientswillreceiveinformationaboutthestudy,includingtheirpersonalresults. 3.8 3.6 3.4 3.1 4.1
Possiblerisksofstudytreatment* 3.8 3.6 3.3 3.1 4.0
Doctor’smotivationsfordoingthestudy 4.1 3.5 3.4 3.3 3.8
Possiblesideeffectsofstudytreatment* 3.7 3.6 3.3 3.2 3.6
Otherwaysofgettingtreatmentbesidesstudyparticipation 3.7 3.4 3.3 2.8 2.9
Nrange= 13-19 156-180 150-171 52-65 9-10
ConfidencethatStudyPatientsareFullyandHonestlyInformedbyAge
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005(unadjustedformultipletests)
![Page 43: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/43.jpg)
43
Particularlyfortheaspectsofclinicaltrialinformationaboutwhichpatientsoverallwerelessconfident(towardthebottomofthetable),therewasgenerallyaninverserelationshipbetweeneducationalattainmentandconfidenceintheinformationprovided.
Patients’ConfidenceinClinicalTrialInformation:ByEducationalAttainment
Meanratingsonascaleof1(notatallconfident)to5(veryconfident)
Advanceddegree
Completedcollegedegree
Somecollege
Completedhighschool
Righttodropoutofthestudy 4.2 3.9 4.0 4.4
Typesofprocedurestobeperformed 4.1 3.9 3.9 4.0
Possiblebenefitsofstudytreatment 3.9 3.9 4.0 4.1
Overalltimecommitment 3.8 3.8 3.8 4.2
Howpersonalinformationwillbekeptprivate 4.0 3.8 3.7 4.1
Costsassociatedwithstudyparticipation 3.8 3.7 3.7 4.0
Painordiscomforttoexpect 3.6 3.5 3.6 3.7
Ifandhowpatientswillreceiveinformationaboutthestudy,includingtheirpersonalresults* 3.4 3.4 3.4 4.2
Possiblerisksofstudytreatment 3.4 3.3 3.5 3.5
Doctor’smotivationsfordoingthestudy* 3.2 3.3 3.5 4.0
Possiblesideeffectsofstudytreatment 3.3 3.4 3.4 3.6
Otherwaysofgettingtreatmentbesidesstudyparticipation 3.2 3.1 3.3 3.6Nrange= 93-105 126-147 115-139 42-48
ConfidencethatStudyPatientsareFullyandHonestlyInformedbyHighestLevelofEducation(onlycategorieswithN>10)
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005(unadjustedformultipletests)
![Page 44: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/44.jpg)
44
ConfidenceinQualityofClinicalResearchProcess
![Page 45: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/45.jpg)
45
3%
3%
4%
4%
8%
6%
9%
9%
12%
12%
18%
8%
9%
10%
9%
10%
13%
13%
14%
15%
17%
20%
19%
21%
20%
22%
21%
27%
21%
23%
26%
25%
23%
26%
27%
27%
25%
24%
23%
28%
28%
22%
20%
18%
43%
40%
39%
39%
37%
30%
29%
27%
25%
26%
22%
Studyteamscollectpatientstudydatainanhonestandunbiasedway.
Studyteamsperformthestudiesexactlythewaytheyaresupposedto.
Studyteamscollectpatientdatawithenoughattentiontodetailto“getitright.”
Studyteamscarefullymonitorthewell-beingofstudypatients.
Studyteamscareaboutstudypatientsaspeople.
Patientswhotakepartinstudiesfollowinstructionscarefully,includingtakingthedrugexactlyastheyaresupposedto.
Studiesaredesignedtolookatthepossiblebenefitsofdrugsinanhonest,unbiasedway.
Studiesaredesignedtolookatthepossiblerisksofdrugsinanhonest,unbiasedway.
Pharmaceuticalcompaniesreportonstudydatainanhonestandunbiasedway.
Pharmaceuticalcompaniescarefullymonitorthewell-beingofstudypatients.
Pharmaceuticalcompaniescareaboutstudypatientsaspeople.
1- Notatallconfident 2 3 4 5- Veryconfident
Mean N
4.0 442
3.9 434
3.9 440
3.8 442
3.7 430
3.6 430
3.5 454
3.5 456
3.3 415
3.3 416
3.1 414
Mostpatientshadatleastafairlevelofconfidenceinthecompliance,caring,andethicsofthesitestudyteamsandpatientsinvolvedinclinicaltrials.However,manywereskepticalaboutthehonestyofpharmaceuticalcompaniesandabouttheextenttowhichtheycaredaboutstudypatients.
Patients’ConfidenceinClinicalTrialComplianceandEthics
Whenitcomestoclinicaltrialsrunbypharmaceuticalcompanies,whatisyourlevelofconfidenceineachofthefollowing?
![Page 46: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/46.jpg)
46
3.0
3.5
4.0
4.5
5.0
3.0 3.5 4.0 4.5 5.0
Patie
nts
Sponsor/CROAQCMembers
Studiesaredesignedtoanswerquestionsaboutbenefits/risksinhonest/unbiasedway.
Pharmacompaniescarefullymonitorthewellbeingofstudypatients.
Pharmacompaniesreportonstudydatainanhonest/unbiasedway.
Pharmacompaniescareaboutstudypatientsaspeople.
SponsorN=95-99,CRON=75-83;PatientsN=414-456
Patientstakingpartinclinicalstudiesfollowinstructionscarefully.
Onaverage,bothpatientsandAQCMemberrespondentswereslightlyskepticalaboutthecomplianceofpatientstakingpartinclinicalstudies.However,patientsweremuchmoreskepticalaboutthehonestyandcaringofpharmaceuticalcompaniesthanwereAQCMembers.
Patientvs.AQCMemberConfidenceinSponsors’andPatients’ClinicalTrialComplianceandEthics
Levelofconfidencethat…MeanRatings:1=NotAtAllConfidentto5=VeryConfident
![Page 47: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/47.jpg)
47
3.0
3.5
4.0
4.5
5.0
3.0 3.5 4.0 4.5 5.0
Patie
ntsw
ithClinicalTria
lHistory
Sponsor/CROAQCMembers
Studiesaredesignedtoanswerquestionsaboutbenefits/risksinhonest/unbiasedway.
Pharmacompaniescarefullymonitorthewellbeingofstudypatients.
Pharmacompaniesreportonstudydatainanhonest/unbiasedway.
Pharmacompaniescareaboutstudypatientsaspeople.
SponsorN=95-99,CRON=75-83;PatientsN=178-201
Patientstakingpartinclinicalstudiesfollowinstructionscarefully.
Again,muchofthepatient-sponsordifferenceinconfidencewasdrivenbypatientswithnoexperienceinclinicaltrials;patientswithclinicaltrialexperiencehadsubstantiallygreaterlevelsofconfidence– muchclosertothelevelsexhibitedbyAQCmembers– thandidthosewithnohistoryofclinicaltrialparticipation(thisslideandnext).
Patientvs.AQCMemberConfidenceinSponsors’andPatients’ClinicalTrialComplianceandEthics
Levelofconfidencethat…MeanRatings:1=NotAtAllConfidentto5=VeryConfident
![Page 48: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/48.jpg)
48
3.0
3.5
4.0
4.5
5.0
3.0 3.5 4.0 4.5 5.0
Patie
ntsw
ithou
tClinicalTria
lHistory
Sponsor/CROAQCMembers
Studiesaredesignedtoanswerquestionsaboutbenefits/risksinhonest/unbiasedway.
Pharmacompaniescarefullymonitorthewellbeingofstudypatients.
Pharmacompaniesreportonstudydatainanhonest/unbiasedway.
Pharmacompaniescareaboutstudypatientsaspeople.
SponsorN=95-99,CRON=75-83;PatientsN=230-258
Patientstakingpartinclinicalstudiesfollowinstructionscarefully.
Levelofconfidencethat…MeanRatings:1=NotAtAllConfidentto5=VeryConfident
PatientswithNoClinicalTrialHistoryvs.AQCMemberConfidenceinSponsors’andPatients’ClinicalTrialComplianceandEthics
![Page 49: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/49.jpg)
49
Whenaskedhowwellpatient-centricthinkingisincorporatedintothedesignandexecutionofclinicaltrials,bothSponsorsandCROsratethemselvessimilarly,moreorlessintheneutralrange.However,bothgroupsratetheirpartnerslowerandtowardsamoreneutralpositionthantheyseethemselves.
AQCMembers:PerceptionsofPatient-CentricThinking
PerceptionsofPatientCentricityinTrialDesign&ExecutionMeanRatings:1=NotWellAtAllto5=VeryWell
5%
5%
2%
2%
22%
12%
17%
7%
32%
28%
40%
27%
30%
31%
34%
40%
11%
23%
7%
23%
Sponsorsyouworkwith
Yourcompany
YourClinicalServiceProviders
Yourcompany
Mean
3.2
3.6
3.3
3.7
SponsorN=88-95,CRON=76-81Q:PleaserateyourcompanyandyourClinicalServiceProviders/Sponsorsyouhaveworkedwithinthepastyearonhowwellpatient-centricthinkingisincorporatedintothedesignandexecutionofclinicaltrials.
Sponsor
CRO
![Page 50: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/50.jpg)
50
Meanratingsonascaleof1(notatallconfident)to5(veryconfident) Chronic Degenerative Episodic
Studyteamscollectpatientstudydatainanhonestandunbiasedway. 4.0 3.9 3.9Studyteamsperformthestudiesexactlythewaytheyaresupposedto. 4.0 3.8 3.8Studyteamscollectpatientdatawithenoughattentiontodetailto“getitright.” 3.9 3.8 3.8
Studyteamscarefullymonitorthewell-beingofstudypatients. 3.9 3.7 3.9Studyteamscareaboutstudypatientsaspeople. 3.8 3.6 3.6Patientswhotakepartinstudiesfollowinstructionscarefully,includingtakingthedrugexactlyastheyaresupposedto. 3.6 3.5 3.6
Studiesaredesignedtolookatthepossiblebenefitsofdrugsinanhonest,unbiasedway. 3.6 3.4 3.5
Studiesaredesignedtolookatthepossiblerisksofdrugsinanhonest,unbiasedway.** 3.6 3.3 3.3
Pharmaceuticalcompaniesreportonstudydatainanhonestandunbiasedway. 3.4 3.1 3.4
Pharmaceuticalcompaniescarefullymonitorthewell-beingofstudypatients. 3.4 3.1 3.6
Pharmaceuticalcompaniescareaboutstudypatientsaspeople. 3.2 2.8 3.0Nrange= 232-263 123-141 38-41
Patientswithchronicconditionswereonaveragemoreconfidentthanothersinthecompliance,ethics,andcaringofthoseexecutingclinicaltrials,andthosewithdegenerativeconditionsweregenerallyleastconfident.
Patients’ConfidenceinTrialCompliance/Ethics:ByTypeofCondition
ConfidenceinClinicalTrialComplianceandEthicsbyTypeofMedicalCondition(onlycategorieswithN>10)
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005(unadjustedformultipletests)
![Page 51: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/51.jpg)
51
Onaverage,patientswithmilddiseaseweremoreconfidentthanothersinthecompliance,ethics,andcaringofthoseexecutingclinicaltrials,andthosewithmoderateorvariableseverityweregenerallyleastconfident.
Patients’ConfidenceinTrialCompliance/Ethics:ByImpactofCondition
Meanratingsonascaleof1(notatallconfident)to5(veryconfident) Severe Moderate Mild Itvaries None
Studyteamscollectpatientstudydatainanhonestandunbiasedway. 4.0 3.9 4.2 3.9 4.0
Studyteamsperformthestudiesexactlythewaytheyaresupposedto. 4.0 3.8 4.2 3.9 4.0
Studyteamscollectpatientdatawithenoughattentiontodetailto“getitright.” 3.9 3.8 4.1 3.8 3.9
Studyteamscarefullymonitorthewell-beingofstudypatients. 3.8 3.7 4.1 3.8 4.0Studyteamscareaboutstudypatientsaspeople. 3.7 3.6 4.1 3.6 3.9Patientswhotakepartinstudiesfollowinstructionscarefully,includingtakingthedrugexactlyastheyaresupposedto. 3.6 3.5 3.6 3.6 3.8
Studiesaredesignedtolookatthepossiblebenefitsofdrugsinanhonest,unbiasedway. 3.5 3.4 3.9 3.4 3.6
Studiesaredesignedtolookatthepossiblerisksofdrugsinanhonest,unbiasedway. 3.5 3.4 3.8 3.3 3.8
Pharmaceuticalcompaniesreportonstudydatainanhonestandunbiasedway. 3.3 3.2 3.8 3.2 3.4
Pharmaceuticalcompaniescarefullymonitorthewell-beingofstudypatients.* 3.2 3.2 3.8 3.2 3.5
Pharmaceuticalcompaniescareaboutstudypatientsaspeople. 3.0 2.9 3.5 3.0 3.2Nrange= 124-139 144-159 60-72 53-59 25-29
ConfidenceinClinicalTrialComplianceandEthicsbyImpactofMedicalCondition
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005(unadjustedformultipletests)
![Page 52: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/52.jpg)
52
Onaverage,patientswhosawtheirtreatingphysiciansfrequentlyweremoreskepticalaboutthecompliance,ethics,andcaringofthoseexecutingclinicaltrialsthanwerethosewhosawtheirproviderslessfrequently.
Patients’ConfidenceinTrialCompliance/Ethics:ByFrequencyofCare
Meanratingsonascaleof1(notatallconfident)to5(veryconfident)
Morethan12timesperyear
5to12times
peryear
2to4times
peryear
Onceperyearorless
Itdepends
Studyteamscollectpatientstudydatainanhonestandunbiasedway. 3.9 3.8 4.0 4.1 4.0
Studyteamsperformthestudiesexactlythewaytheyaresupposedto. 3.9 3.7 4.0 4.1 4.0
Studyteamscollectpatientdatawithenoughattentiontodetailto“getitright.” 3.6 3.7 4.0 3.9 3.9
Studyteamscarefullymonitorthewell-beingofstudypatients. 3.8 3.6 3.9 3.9 4.1Studyteamscareaboutstudypatientsaspeople. 3.5 3.4 3.8 3.9 3.9Patientswhotakepartinstudiesfollowinstructionscarefully,includingtakingthedrugexactlyastheyaresupposedto. 3.4 3.6 3.6 3.6 3.5
Studiesaredesignedtolookatthepossiblebenefitsofdrugsinanhonest,unbiasedway. 3.3 3.3 3.6 3.6 3.7
Studiesaredesignedtolookatthepossiblerisksofdrugsinanhonest,unbiasedway. 3.5 3.4 3.5 3.6 3.5
Pharmaceuticalcompaniesreportonstudydatainanhonestandunbiasedway. 3.2 3.0 3.4 3.5 3.3
Pharmaceuticalcompaniescarefullymonitorthewell-beingofstudypatients. 3.1 3.2 3.4 3.5 3.3
Pharmaceuticalcompaniescareaboutstudypatientsaspeople. 2.9 2.9 3.1 3.2 3.1Nrange= 38-43 78-88 202-224 43-51 42-49
ConfidenceinClinicalTrialComplianceandEthicsbyFrequencyofCare
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005(unadjustedformultipletests)
![Page 53: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/53.jpg)
53
Onaverage,patientswhohadparticipatedinclinicaltrialsweremoreconfidentinthecompliance,ethics,andcaringofthoseexecutingclinicaltrialsthanwerethosewhohadnot.
Patients’ConfidenceinTrialCompliance/Ethics:ByHistoryofTrialParticipation
Meanratingsonascaleof1(notatallconfident)to5(veryconfident) Yes No
Studyteamscollectpatientstudydatainanhonestandunbiasedway.*** 4.2 3.8
Studyteamsperformthestudiesexactlythewaytheyaresupposedto.* 4.1 3.8
Studyteamscollectpatientdatawithenoughattentiontodetailto“getitright.”**** 4.1 3.7
Studyteamscarefullymonitorthewell-beingofstudypatients.*** 4.1 3.7
Studyteamscareaboutstudypatientsaspeople.*** 4.0 3.5
Patientswhotakepartinstudiesfollowinstructionscarefully,includingtakingthedrugexactlyastheyaresupposedto. 3.6 3.5
Studiesaredesignedtolookatthepossiblebenefitsofdrugsinanhonest,unbiasedway.*** 3.8 3.4
Studiesaredesignedtolookatthepossiblerisksofdrugsinanhonest,unbiasedway.** 3.7 3.4
Pharmaceuticalcompaniesreportonstudydatainanhonestandunbiasedway.** 3.5 3.2
Pharmaceuticalcompaniescarefullymonitorthewell-beingofstudypatients. 3.5 3.2
Pharmaceuticalcompaniescareaboutstudypatientsaspeople. 3.2 3.0
Nrange= 178-201 230-258
ConfidenceinClinicalTrialComplianceandEthicsbyHistoryofTrialParticipation
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005;****p<.0001(unadjustedformultipletests)
![Page 54: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/54.jpg)
54
Ingeneral,therewasaninverserelationshipbetweenlevelofeducationalattainmentandconfidenceinthecompliance,ethics,andcaringofthoseexecutingclinicaltrials.
Patients’ConfidenceinTrialCompliance/Ethics:ByEducationalAttainment
Meanratingsonascaleof1(notatallconfident)to5(veryconfident)
Advanceddegree
Completedcollegedegree
Somecollege
Completedhighschool
Studyteamscollectpatientstudydatainanhonestandunbiasedway.* 3.8 4.0 4.0 4.3Studyteamsperformthestudiesexactlythewaytheyaresupposedto.** 3.7 3.9 3.9 4.3Studyteamscollectpatientdatawithenoughattentiontodetailto“getitright.”* 3.7 3.8 3.9 4.3
Studyteamscarefullymonitorthewell-beingofstudypatients. 3.7 3.9 3.9 4.1Studyteamscareaboutstudypatientsaspeople. 3.4 3.8 3.8 4.0Patientswhotakepartinstudiesfollowinstructionscarefully,includingtakingthedrugexactlyastheyaresupposedto.* 3.3 3.5 3.7 3.7
Studiesaredesignedtolookatthepossiblebenefitsofdrugsinanhonest,unbiasedway. 3.3 3.6 3.6 3.8
Studiesaredesignedtolookatthepossiblerisksofdrugsinanhonest,unbiasedway. 3.3 3.6 3.4 3.8
Pharmaceuticalcompaniesreportonstudydatainanhonestandunbiasedway.** 2.9 3.4 3.4 3.7
Pharmaceuticalcompaniescarefullymonitorthewell-beingofstudypatients.* 3.0 3.4 3.3 3.7
Pharmaceuticalcompaniescareaboutstudypatientsaspeople.** 2.7 3.1 3.1 3.5Nrange= 100-109 129-144 131-149 40-48
ConfidenceinClinicalTrialComplianceandEthicsbyHighestLevelofEducation(categorieswithN>10only)
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005;****p<.0001(unadjustedformultipletests)
![Page 55: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/55.jpg)
55
Ingeneral,patientsbetween31and60yearsofagewerelessconfidentinthecompliance,ethics,andcaringofthoseinvolvedinclinicaltrialexecutionthanwereyoungerorolderpatients.Thoseinthe76+agegrouphadthehighestlevelofconfidence.
Patients’ConfidenceinTrialCompliance/Ethics:ByAgeGroup
Meanratingsonascaleof1(notatallconfident)to5(veryconfident) 76+ 61-75 46-60 31-45 18-30
Studyteamscollectpatientstudydatainanhonestandunbiasedway.* 4.5 4.1 3.9 3.7 3.9
Studyteamsperformthestudiesexactlythewaytheyaresupposedto.** 4.6 4.1 3.8 3.7 4.0
Studyteamscollectpatientdatawithenoughattentiontodetailto“getitright.” 4.3 4.0 3.8 3.6 4.0
Studyteamscarefullymonitorthewell-beingofstudypatients. 4.3 3.9 3.8 3.7 3.9Studyteamscareaboutstudypatientsaspeople. 4.4 3.8 3.7 3.5 3.5Patientswhotakepartinstudiesfollowinstructionscarefully,includingtakingthedrugexactlyastheyaresupposedto. 4.1 3.6 3.5 3.5 3.6
Studiesaredesignedtolookatthepossiblebenefitsofdrugsinanhonest,unbiasedway. 4.1 3.7 3.4 3.4 3.6
Studiesaredesignedtolookatthepossiblerisksofdrugsinanhonest,unbiasedway.* 4.2 3.6 3.4 3.3 3.6
Pharmaceuticalcompaniesreportonstudydatainanhonestandunbiasedway. 3.9 3.4 3.2 3.3 3.3
Pharmaceuticalcompaniescarefullymonitorthewell-beingofstudypatients. 3.8 3.4 3.3 3.2 3.2
Pharmaceuticalcompaniescareaboutstudypatientsaspeople. 3.6 3.1 3.1 3.0 2.6Nrange= 14-20 162-182 160-177 59-65 9-12
ConfidenceinClinicalTrialComplianceandEthicsbyAge
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005;****p<.0001(unadjustedformultipletests)
![Page 56: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/56.jpg)
56
Onaverage,patientswhowereresponsibleforprovidingdirectcareorfinancialsupportoffamilymembersweremoreskepticalaboutthecompliance,ethics,andcaringofthoseexecutingclinicaltrialsthanwerethosewhowerenot.
Patients’ConfidenceinTrialCompliance/Ethics:ByFamilyResponsibility
Meanratingsonascaleof1(notatallconfident)to5(veryconfident)
Yes (providescareorfinancial supporttofamilymembers)
No
Studyteamscollectpatientstudydatainanhonestandunbiasedway.* 3.8 4.1
Studyteamsperformthestudiesexactlythewaytheyaresupposedto.* 3.8 4.0
Studyteamscollectpatientdatawithenoughattentiontodetailto“getitright.”* 3.7 4.0
Studyteamscarefullymonitorthewell-beingofstudypatients. 3.7 3.9
Studyteamscareaboutstudypatientsaspeople. 3.7 3.7
Patientswhotakepartinstudiesfollowinstructionscarefully,includingtakingthedrugexactlyastheyaresupposedto. 3.4 3.7
Studiesaredesignedtolookatthepossiblebenefitsofdrugsinanhonest,unbiasedway.* 3.4 3.6
Studiesaredesignedtolookatthepossiblerisksofdrugsinanhonest,unbiasedway.* 3.3 3.6
Pharmaceuticalcompaniesreportonstudydatainanhonestandunbiasedway.* 3.2 3.4
Pharmaceuticalcompaniescarefullymonitorthewell-beingofstudypatients. 3.2 3.4
Pharmaceuticalcompaniescareaboutstudypatientsaspeople. 2.9 3.1Nrange= 165-186 246-270
ConfidenceinClinicalTrialComplianceandEthicsbyFamilyResponsibility
Note:Highestmeanperrowhighlightedinyellow,lowestinred.*p<.05;**p<.01;***p<.005;****p<.0001(unadjustedformultipletests)
![Page 57: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/57.jpg)
57
ThemesinOpen-EndedCommentsPatientViewsonActionsthatInfluenceConfidence
• Interactionwithpatientsforfeedbackaboutstudydesignandoperations
– “Theydon’tinteractwithparticipantstogetfeedbackonwhatwasgoodorbadaboutthestudy.”
– “Evidenceofincludingpatientparticipationintrials’creation,monitoring,andmeasurementofassessmentusingviabletools.”
• Faircompensation,andcaring,respectful,andequitabletreatmentasparticipantsintheresearchprocess:
– “Whiletheprotocolispatient-centered,theback-upandbedsidemannerdonotalwayswork.”
– “Careaboutpatientsaspeople?Ha!Thenwhyarewecalled‘subjects’??Andwhyaren’twecompensatedmuchbetterandsoonerinthestudy?Thesponsorsmakeobsceneamountsofmoneyandskipwhenitcomestoallaspectsofpatientinteraction.Whyarethevisitsalwayssoinconvenient?Whyaren’tthereeveningandweekendhours?Whyaren’tstafftrainedininterpersonalcommunication,especiallythechiefinvestigatingphysician?”
– “Itboilsdowntotheirtakingtimewithme.Beingtransparentaboutwhattheyaredoingstep-by-stepandexplainingwhatisgoingon.”
![Page 58: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/58.jpg)
58
ThemesinOpen-EndedComments,continuedPatientViewsonActionsthatInfluenceConfidence
• Averylargenumberofcommentshadtodowithbusinessconcerns.Whilepatientsweremostlikelytocitetheprofitmotivesofpharmaceuticalcompaniesormedicalpractitionersasahugesourceofdistrust,somealsoderivedconfidencefromthisfact,reflectingthat“findingthetruth”madegoodbusinesssenseandthatanyunethicalconductwouldreturnpoorlyinthelongtermbothintermsofproductinvestmentsandintermsofliabilities.
– “Themedicalandpharmaceuticalindustries’mainpriorityismoney!Whenmoneyisthemostimportantthing,peoplearenottoldcompleteinformation.It’sabasicconflictofinterest!”
– “Re.doctors’motivations,Idon’trememberthisparticularaspectofeithertrialweparticipatedin,orthevariousothertrialsIconsidered,everhavingbeenmentioned.”
– “Ithinkmostofthemunderstandthatforlong-termsuccesstheyneedtodevelopdrugsthataregoodforbothpatientsandtheircompany,soincentivesarealignedinsomerespect.”
– “I’vebeentoconferenceswherethemainspeakeristryingtoconvincepeopletoparticipateinclinicaltrials.Noneofthesideeffectswereaddressed.Itwastrulya‘salespitch.’”
![Page 59: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/59.jpg)
59
ThemesinOpen-EndedComments,continuedPatientViewsonActionsthatInfluenceConfidence
• Manypatientsreportthattheirconfidenceintheteamsperformingclinicalstudiescomeslargelyfromtheirfaiththatthesepartiesaregovernedbyregulationsandmonitoringbodies(includingethicscommittees),andfearfuloflawsuits.
• Manyalsoreportconfidencesimplyintheprofessionalismandgoodintentionsofresearchers,practitioners,andinstitutionsoperatinginthemedicalfield.
• Perceivedtransparencyintheareasofstudyprocedures,studyresults,drugrisks,IRBinteractions,doctormotivations,etc.wasregardedasasourceofconfidencebypatientswhohadexperiencedsuchtransparency.Conversely,alackoftransparencyintheserespects,particularlyinthedisseminationofresults,wascitedasasourceofdistrust.
– “Theteam…madesureIunderstoodeverythingaboutthestudyandwasquicktorespondwhenanyquestioncameup.”
– “IaskedforfeedbackafterthestudyIdidparticipateinandneverreceivedit.Iknowofno-onewhotrustspharmaceuticalcompanies.”“IfeelasthoughIhavebeenforgotten.”
• Mediareportsregardingcorruptionanddrugrecalls,andlawyer’sadvertisementsregardingclassactionsuits,werecitedassourcesofdistrustintheindustry.
![Page 60: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/60.jpg)
60
PerspectivesonClinicalTrialParticipation
![Page 61: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/61.jpg)
61
Nearlyhalfofthepatientsurveyedhadparticipatedinaclinicaltrial.Themostcommonreasonfordoingsowastheopportunitytocontributetoscience,followedbytheopportunitytolearnmoreabouttheirconditionsandbypaymentforparticipation.Themajorityofclinicaltrialparticipantsreportedfeelingmoreeducatedandinvolvedintheiroverallhealthasaresult.
PatientSurvey:ClinicalTrialParticipationRateandReasons
Whydidyoudecidetoparticipateintheclinicaltrial?
69%
51%
39%
21%
15%
15%
10%
2%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwouldotherwiseget
AccesstobetterdoctorsandhospitalsthanIwouldotherwisebeabletouse
Other
Influencedbymyfamily/friends65%14%
21% Yes
Notsure
No
N=302
45%55%
Yes
No
Haveyoueverparticipatedinaclinicaltrial?
N=582
Ifyes,didyoufeelmoreeducatedandinvolvedinyouroverallhealthasaresult?
N=260
![Page 62: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/62.jpg)
62
52%
48%
36%
16%
0%
4%
12%
0%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwould…
AccesstobetterdoctorsandhospitalsthanIwould…
Other
Influencedbymyfamily/friends
71%
60%
36%
17%
17%
13%
9%
1%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwould…
AccesstobetterdoctorsandhospitalsthanIwould…
Other
Influencedbymyfamily/friends
Whydidyoudecidetoparticipateintheclinicaltrial?byTypeofMedicalCondition
71%
47%
41%
24%
18%
16%
11%
3%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwouldotherwiseget
AccesstobetterdoctorsandhospitalsthanIwouldotherwisebe
abletouse
Other
Influencedbymyfamily/friends
N156
70
25
Thereweresomedifferencesacrosspatientswithdifferenttypesofmedicalconditionsinthereasonsfordecidingtoparticipateinclinicaltrials.Althoughthetopfourreasonswereallthesame,andinthesameorder,patientswithchronicanddegenerativeconditionsgenerallyendorsedmorereasonsfortrialparticipationthandidthosewithepisodicconditions,particularlyincludingadesireformorecontactwithdoctors/nurses,andaccesstobetterhospitalsanddoctors,thantheywouldotherwiseget.
PatientSubsets:TypeofMedicalCondition
Chronic
Degenerative
Episodic
![Page 63: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/63.jpg)
63
63%
48%
33%
28%
11%
17%
9%
0%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwould…
AccesstobetterdoctorsandhospitalsthanIwould…
Other
Influencedbymyfamily/friends
72%
55%
39%
18%
17%
11%
6%
3%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwould…
AccesstobetterdoctorsandhospitalsthanIwould…
Other
Influencedbymyfamily/friends
PatientSubsets:ImpactofMedicalCondition
Whydidyoudecidetoparticipateintheclinicaltrial?byImpactofMedicalCondition
70%
55%
36%
18%
15%
20%
15%
3%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwouldotherwiseget
AccesstobetterdoctorsandhospitalsthanIwouldotherwisebe
abletouse
Other
Influencedbymyfamily/friends
N66
94
54
28
14
Severe
Moderate
Mild
Itvaries
None
Therewerealsodifferencesacrosspatientswithdifferentseveritiesofmedicalconditions.Althoughagainthetopthreereasonsfortrialparticipationwereallthesame,patientswithmilddiseaseweremorelikelytobeinfluencedbyaccesstofreehealthcarethanwerethosewithmoreseriousconditions,andthosewithnoimpactweremorelikelytobeinfluencedbypayment(seenextslide).
![Page 64: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/64.jpg)
64
71%
36%
50%
14%
14%
7%
14%
0%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwould…
AccesstobetterdoctorsandhospitalsthanIwould…
Other
Influencedbymyfamily/friends
PatientSubsets:ImpactofMedicalCondition(continued)
Whydidyoudecidetoparticipateintheclinicaltrial?byImpactofMedicalCondition
71%
50%
43%
29%
18%
14%
11%
4%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwouldotherwiseget
AccesstobetterdoctorsandhospitalsthanIwouldotherwisebe
abletouse
Other
Influencedbymyfamily/friends
N66
94
54
28
14
Severe
Moderate
Mild
Itvaries
None
![Page 65: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/65.jpg)
65
65%
53%
48%
25%
15%
23%
5%
0%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwould…
AccesstobetterdoctorsandhospitalsthanIwould…
Other
Influencedbymyfamily/friends
PatientSubsets:EmploymentStatus
Whydidyoudecidetoparticipateintheclinicaltrial?byCurrentEmployment
74%
42%
32%
21%
15%
13%
10%
3%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwouldotherwiseget
AccesstobetterdoctorsandhospitalsthanIwouldotherwisebe
abletouse
Other
Influencedbymyfamily/friends
N62
40
88
70
Fulltime
Parttime
Retired
No
Notsurprisingly,employmentstatusalsoinfluencedpatients’decision-makingcriteria(thisslideandnext).Againthetopthreereasonsfortrialparticipationwereallthesame,however,fullyemployedpatientswerelesslikelythanotherstobeinfluencedbypaymentorbytheopportunitytolearnabouttheirconditions,andmorelikelytobeinfluencedbythechancetocontributetoscience.
![Page 66: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/66.jpg)
66
71%
59%
34%
20%
11%
21%
11%
1%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwould…
AccesstobetterdoctorsandhospitalsthanIwould…
Other
Influencedbymyfamily/friends
PatientSubsets:EmploymentStatus(continued)
Whydidyoudecidetoparticipateintheclinicaltrial?byCurrentEmployment
66%
50%
43%
19%
19%
7%
11%
3%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwouldotherwiseget
AccesstobetterdoctorsandhospitalsthanIwouldotherwisebe
abletouse
Other
Influencedbymyfamily/friends
N62
40
88
70
Fulltime
Parttime
Retired
No
![Page 67: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/67.jpg)
67
67%
51%
36%
19%
13%
7%
14%
2%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwould…
AccesstobetterdoctorsandhospitalsthanIwould…
Other
Influencedbymyfamily/friends
PatientSubsets:AgeGroup
Whydidyoudecidetoparticipateintheclinicaltrial?byAge(onlycategorieswithN>10)
71%
57%
29%
21%
36%
14%
14%
0%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwouldotherwiseget
AccesstobetterdoctorsandhospitalsthanIwouldotherwisebe
abletouse
Other
Influencedbymyfamily/friends
N
14
95
82
18
76+
61-75
46-60
31-45
Agegroupappearedtohaveasubstantialimpactonpatients’decision-makingcriteria(thisslideandnext),thoughtheNsinsomegroupsweresmall.Forolderpatients(76+),theadditionalexpectedcontactwithdoctorsandnurseswasakeyreasonforparticipation,whereasforyoungerpatients(31-60),accesstobetterdoctorsandhospitalswasmorelikelytobeakeyfactor.
![Page 68: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/68.jpg)
68
72%
50%
33%
22%
17%
22%
6%
6%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwould…
AccesstobetterdoctorsandhospitalsthanIwould…
Other
Influencedbymyfamily/friends
PatientSubsets:AgeGroup(continued)
Whydidyoudecidetoparticipateintheclinicaltrial?byAge
68%
55%
44%
24%
12%
17%
9%
1%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwouldotherwiseget
AccesstobetterdoctorsandhospitalsthanIwouldotherwisebe
abletouse
Other
Influencedbymyfamily/friends
N
14
95
82
18
76+
61-75
46-60
31-45
![Page 69: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/69.jpg)
69
64%
50%
31%
21%
17%
14%
10%
5%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwould…
AccesstobetterdoctorsandhospitalsthanIwould…
Other
Influencedbymyfamily/friends
PatientSubsets:Sex
Whydidyoudecidetoparticipateintheclinicaltrial?bySex
71%
54%
41%
22%
13%
13%
11%
1%
Opportunitytocontributetoscience
Opportunitytolearnmoreaboutmycondition
Iwaspaidtoparticipate
Accesstofreehealthcare
Morecontactwithdoctors/nursesthanIwouldotherwiseget
AccesstobetterdoctorsandhospitalsthanIwouldotherwisebe
abletouse
Other
Influencedbymyfamily/friends
N
150
58
Female
Male
Femalesingeneralendorsedmorereasonsforparticipatinginclinicaltrialsthandidmales,thoughtheoverallpatternoftopreasonswasthesame.
![Page 70: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/70.jpg)
70
ThemajorityofbothAQCMembersandPatientsstatedthattheywouldrecommendclinicalresearchparticipationtoalovedoneorfriend,butmanyineachgroupstatedthattheyweren’tsure.Amongthosenotsure,severityofdiseaseandavailabilityofotheroptionswerevolunteeredascommentsforambivalence.
WillingnesstoRecommendClinicalResearchParticipation
82%
2%16% Yes
No
Notsure 67%4%
29% Yes
No
Notsure
SponsorN=102,CRON=85;PatientsN=422Q:Basedonyourexperience,wouldyourecommendclinicalresearchparticipationtoalovedoneorfriend?
Sponsor/CROAQCMembers Patients
![Page 71: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/71.jpg)
71
Amongthosewhoresponded“Yes”,responsescarriedthemesofconsiderationofrisksandbenefits,oftheinstitutionsatwhichthestudiesarebeingperformed,andofawishto“dogood”forsociety.“No”responsesgenerallyreflecteddistrustoftheindustry.
Patients:ClinicalTrialParticipation
• “Itwoulddependonthedrugsinvolved,lengthoftime,andseverityofmyfriend’scondition.”• “Ifit’sadouble-blindtrialwithplacebo,thenI’mhesitanttoparticipateorrecommendparticipationbecauseImightwindupgoingwithoutmedicationforaconditionthatneedsmedicating.”• “Ionlydoitforthemoney.”• “Ifmorepeopledon’tparticipateinclinicalresearch,thentheymightaswellconsiderthemselvesasbeingexperimentedonwithmarketeddrugs.”• “Don’tgoinblindanddumb.Askplentyofquestions.Itwouldhelpifpatientsgotacrashcourseinwhatthestudywasaboutandwhattoexpectintheformofapamphlet.Neverseenthatbefore.Everythingisvague,politicallycorrect,andgeneral…Wealsoneedtobecompensatedbetter,likewematterasmuchastherestofthestudyteam.”• “Scienceneedsallthehelpitcanget.”• “Iwanttohelppeople.EvenifIendupintheplacebogroup.”
PatientsN=422Q:Basedonyourexperience,wouldyourecommendclinicalresearchparticipationtoalovedoneorfriend?
![Page 72: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/72.jpg)
72
Amongthosewhoresponded“Yes”,responsescarriedacommonthemeofdirecircumstance(lifethreateningdisease/absenceofotheroptions)andconsiderationofrisksandbenefits.“No”responsesdidnotoffercomments.
AQCMembers:ClinicalTrialParticipation
• “IwouldparticipateinaclinicaltrialmyselfifitwasfortreatmentforaconditionIwassufferingfromandIbelievedthatthistrialcouldbenefitmeandsociety.”• “Ofcourse,Iwouldsaythatnotalltrialsarecreatedequalandthelovedoneorfriendshouldevaluatetheconsentdocumentcarefully,asklotsofquestions,andaskforadditionalsourcesofinformation.”• “Iftherearelimitedtreatmentswhichareapprovedandavailabletoafamilymember,Iwoulddefinitelyrecommendaclinicaltrialapproach.”• “PhaseIhealthyvolunteerswithNME- NO!Ifloved-one/friendhadalife-threateningdiseaseandtreatmentoptionswerelimitedthenIwouldrecommendtheyfindoutaboutappropriateclinicaltrial.”• “Oncology,forsure.Lessconfidentaboutotherindications.”• “Thereneedstobemoreinformationforpatientsontrials,andmoretrialsincriticalareas(e.g.autism).”• “Iwouldforsurerecommendparticipationinatrial,whenthereisenoughinformationgivenontherisk-benefitratio,sideeffectsandotherpotentialtreatmentsoutsideofatrial.”• “IwouldrecommendEXPLORINGclinicaltrialresearchparticipationbasedontheethicsappliedbythecompaniesthatgenerallysponsorandexecutethem,butclinicalresearchcomeswithinherentrisk;thepotentialrisksneedtobewellunderstoodbeforecommitting.”
SponsorN=102,CRON=85Q:Basedonyourexperience,wouldyourecommendclinicalresearchparticipationtoalovedoneorfriend?
![Page 73: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/73.jpg)
73
AQCMemberSurvey:Perceptionsof
ClinicalResearchQuality
![Page 74: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/74.jpg)
74
PerceptionsofQualityOverTimeThoughtherecontinuestobeadifferencebetweenCROsatisfactionwithqualitydeliveredandsatisfactionwithqualityreceivedamongSponsors,anupwardtrendinSponsorratingsisdrivingamovetowardsconvergenceatanoverallhigherlevelofsatisfactionwithqualitydeliveredascomparedto2012.
SponsorN=101,CRON=85SponsorQ:ThinkingaboutyourexperienceswithClinicalServiceProvidersyouworkedwithin2015,howsatisfiedareyouwith…thequalitydeliveredbyyourClinicalServiceProviders?ProviderQ:Thinkingaboutyourexperiencesin2015,howsatisfiedareyouwith…thequalitythatyourcompanydeliveredtoSponsors?
2%18%
5%
13%
5%
55%
54%
12%
36%
Sponsor CRO
5
4
3
2
1
Mean: 3.6 4.2
Verysatisfied
Verydissatisfied 3.3 3.2 3.1
3.43.6
3.84.0 4.1 4.2 4.2
2012 2013 2014 2015 2016
Sponsor CRO
MeanRatingTrend
![Page 75: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/75.jpg)
75
SatisfactiononKeyRelationshipMetricsSponsorsandCROsarecloselyalignedintheirsatisfactionwithrelationships,howevertheydifferintheirperceptionofsatisfactionwithrespecttoquality,overallworkdeliveredandvalueformoney.
3.9
3.6
3.6
3.3
4.2
4.2
4.3
4.3
Sponsor CROYourrelationships withtheCSPswithwhichyouwork
Yourrelationships withtheSponsorswithwhichyouwork
Thequality deliveredbyyourCSPs
Thequality thatyourcompanyhasdeliveredtoSponsors
TheoverallworkthathasbeendoneforyoubyyourCSPs
TheoverallworkthatyourcompanydeliveredforSponsors
Thevalue thatyouhavereceivedforthemoneyspentonyourCSPs
Thevalue thatyourcompanyhasdeliveredforthemoneyreceivedfromSponsors
SponsorN=92-101,CRON=82-85SponsorQ:ThinkingaboutyourexperienceswithClinicalServiceProvidersyouworkedwithin2015,howsatisfiedareyouwith…ProviderQ:Thinkingaboutyourexperiencesin2015,howsatisfiedareyouwith…
![Page 76: AQC 2016 Patient Centered Survey FINAL 10252016theavocagroup.com/.../2017/04/AQC-2016-Patient-Centered-Survey-R… · AQC 2016 Survey Research Final Report of Patient Survey and AQC](https://reader036.vdocuments.site/reader036/viewer/2022081607/5f01c3c77e708231d400ed1d/html5/thumbnails/76.jpg)
TheAvocaQualityConsortiumbringstogetherquality,outsourcingandoperationalprofessionalsfrommemberpharma,biotech,nicheclinicalserviceproviders,andCROorganizationstoaccelerateandstreamlineclinicaltrialexecutionandimprovequalitythroughindustrycollaboration.